BNP PARIBAS FINANCIAL MARKETS - AGIOS PHARMACEUTICALS INC ownership

AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 75 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2014. The put-call ratio across all filers is - and the average weighting 1.5%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of AGIOS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,466,165
-20.9%
59,239
-9.5%
0.00%0.0%
Q2 2023$1,854,394
-27.2%
65,480
-40.9%
0.00%
-50.0%
Q1 2023$2,546,592
+38.4%
110,866
+69.1%
0.00%
+33.3%
Q4 2022$1,840,588
-100.0%
65,548
-54.0%
0.00%
-50.0%
Q3 2022$4,027,270,000
+79.8%
142,407
+41.0%
0.01%
+100.0%
Q2 2022$2,239,791,000
+172.8%
101,028
+258.2%
0.00%
+200.0%
Q1 2022$821,135,000
-29.8%
28,208
-20.8%
0.00%
-50.0%
Q4 2021$1,170,205,000
-8.5%
35,601
+28.4%
0.00%0.0%
Q3 2021$1,279,370,000
+13.6%
27,722
+35.6%
0.00%
+100.0%
Q2 2021$1,126,559,000
+19.9%
20,442
+12.3%
0.00%0.0%
Q1 2021$939,900,000
+0.9%
18,201
-15.3%
0.00%
-50.0%
Q4 2020$931,248,000
-78.6%
21,492
-82.7%
0.00%
-66.7%
Q3 2020$4,354,595,000
-50.6%
124,417
-24.6%
0.01%
-62.5%
Q2 2020$8,821,205,000
+45.7%
164,944
-3.3%
0.02%
+33.3%
Q1 2020$6,053,633,000
-56.2%
170,621
-41.0%
0.01%
-52.0%
Q4 2019$13,820,092,000
+2591.3%
289,426
+1726.1%
0.02%
+2400.0%
Q3 2019$513,508,000
-24.8%
15,849
+15.7%
0.00%0.0%
Q2 2019$683,306,000
-26.2%
13,699
-0.2%
0.00%
-50.0%
Q1 2019$925,344,000
+71.2%
13,721
+17.1%
0.00%
+100.0%
Q4 2018$540,455,000
-25.5%
11,721
+24.5%
0.00%0.0%
Q3 2018$725,853,000
-6.1%
9,412
+2.6%
0.00%0.0%
Q2 2018$772,810,000
-6.3%
9,175
-9.1%
0.00%
-50.0%
Q1 2018$825,078,000
+43.2%
10,089
+0.1%
0.00%
+100.0%
Q4 2017$576,159,000
-29.3%
10,078
-17.5%
0.00%
-50.0%
Q3 2017$815,418,000
+16.7%
12,216
-10.0%
0.00%0.0%
Q2 2017$698,434,000
-9.3%
13,575
+2.9%
0.00%0.0%
Q1 2017$770,296,000
+64.2%
13,190
+17.3%
0.00%0.0%
Q4 2016$469,045,000
-38.3%
11,240
-21.9%
0.00%
-33.3%
Q3 2016$759,974,000
+51.8%
14,388
+20.4%
0.00%
+50.0%
Q2 2016$500,621,000
+2.6%
11,948
-0.6%
0.00%0.0%
Q1 2016$488,093,000
-60.0%
12,022
-36.1%
0.00%
-33.3%
Q4 2015$1,221,664,000
+134.7%
18,818
+155.2%
0.00%
+200.0%
Q3 2015$520,601,000
-38.1%
7,375
-2.6%
0.00%
-50.0%
Q2 2015$841,108,000
+2485.3%
7,568
+2093.6%
0.00%
Q1 2015$32,534,000
-46.6%
345
-65.3%
0.00%
Q3 2014$60,982,000
+3927.9%
994
+2661.1%
0.00%
Q1 2014$1,514,000
+125.6%
36
+28.6%
0.00%
Q4 2013$671,000280.00%
Other shareholders
AGIOS PHARMACEUTICALS INC shareholders Q1 2014
NameSharesValueWeighting ↓
BB BIOTECH AG 2,719,998$155,502,0004.38%
Casdin Capital, LLC 295,000$16,865,0004.11%
Opaleye Management Inc. 130,000$7,432,0002.38%
Opus Point Partners Management, LLC 28,704$1,641,0001.42%
Fernwood Investment Management, LLC 27,550$1,575,0000.84%
Rhenman & Partners Asset Management AB 100,000$5,717,0000.77%
COLUMBIA WANGER ASSET MANAGEMENT LLC 760,116$43,456,0000.65%
Eventide Asset Management 214,000$12,234,0000.64%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 262,984$15,035,0000.59%
CAPITAL GUARDIAN TRUST CO 663,089$37,909,0000.54%
View complete list of AGIOS PHARMACEUTICALS INC shareholders